Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00419484

Enrollment

1000

Registered

2007-01-08

Start date

2004-03-31

Completion date

2008-07-31

Last updated

2007-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy, Dyslipidemia, Hypertension, Type 2 Diabetes

Brief summary

We want to investigate the effects of pioglitazone on cardiovascular events in Japanese patients with type 2 diabetes.

Detailed description

Primary composite endpoints: Cardiovascular death Non-fatal myocardial infarction and angina Non-fatal stroke Renal failure (hemodialysis/doubling of serum creatinine) Secondary endpoints: urinary albumin excretion diabetic retinopathy hyperlipidemia hypertension gout

Interventions

DRUGpioglitazone

Study design

Observational model

DEFINED_POPULATION

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

* type 2 diabetes HbA1c: more than 7% and less than 9%

Exclusion criteria

* insulin treatment

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026